M J Gizycki1, K L Hattotuwa, N Barnes, P K Jeffery. 1. Lung Pathology Unit, Imperial College School of Medicine at the Royal Brompton Hospital, London, UK London Chest Hospital, London, UK.
Abstract
BACKGROUND:Inhaled corticosteroids (ICS) markedly reduce bronchial mucosal inflammation in asthma but whether they have an anti-inflammatory effect in airway tissue in chronic obstructive pulmonary disease (COPD) is unknown. METHODS: A study of endobronchial biopsy samples was conducted as part of a double blind, placebo controlled, randomised trial of parallel design. Patients had mild to moderately severe COPD (FEV(1) 25-80% of predicted) and were given 3 months treatment with ICS, fluticasone propionate (FP; 500 micro g twice daily, n=14) or placebo (n=10). Biopsy tissue taken at baseline and after treatment was examined by transmission electron microscopy to count the numbers of all ultrastructurally distinct inflammatory cells. RESULTS: Compared with their baseline values, FP resulted in a significant decrease (on average 65%) in the numbers of mucosal mast cells (median 7.8 (range 1-33) v 2.8 (1-14), p<0.05). The reductive effect of FP held true when the post-treatment values of the placebo and FP groups were compared: 8.8 (1-24) v 2.8 (1-14) (p<0.05). Unexpectedly, there were significantly more neutrophils in the FP than in the placebo group: 4.0 (0-23) v 1.7 (0-8), respectively (p<0.05). There were no alterations to other cell types including mononuclear cells. Symptoms markedly improved in the patients treated with FP for 3 months. CONCLUSION:Fluticasone propionate given for 3 months to patients with COPD has selective effects on the inflammatory cells in the bronchial mucosa: the reduction in mast cell numbers may account for the improvement in symptoms over this time.
RCT Entities:
BACKGROUND: Inhaled corticosteroids (ICS) markedly reduce bronchial mucosal inflammation in asthma but whether they have an anti-inflammatory effect in airway tissue in chronic obstructive pulmonary disease (COPD) is unknown. METHODS: A study of endobronchial biopsy samples was conducted as part of a double blind, placebo controlled, randomised trial of parallel design. Patients had mild to moderately severe COPD (FEV(1) 25-80% of predicted) and were given 3 months treatment with ICS, fluticasone propionate (FP; 500 micro g twice daily, n=14) or placebo (n=10). Biopsy tissue taken at baseline and after treatment was examined by transmission electron microscopy to count the numbers of all ultrastructurally distinct inflammatory cells. RESULTS: Compared with their baseline values, FP resulted in a significant decrease (on average 65%) in the numbers of mucosal mast cells (median 7.8 (range 1-33) v 2.8 (1-14), p<0.05). The reductive effect of FP held true when the post-treatment values of the placebo and FP groups were compared: 8.8 (1-24) v 2.8 (1-14) (p<0.05). Unexpectedly, there were significantly more neutrophils in the FP than in the placebo group: 4.0 (0-23) v 1.7 (0-8), respectively (p<0.05). There were no alterations to other cell types including mononuclear cells. Symptoms markedly improved in the patients treated with FP for 3 months. CONCLUSION:Fluticasone propionate given for 3 months to patients with COPD has selective effects on the inflammatory cells in the bronchial mucosa: the reduction in mast cell numbers may account for the improvement in symptoms over this time.
Authors: M Saetta; S Baraldo; L Corbino; G Turato; F Braccioni; F Rea; G Cavallesco; G Tropeano; C E Mapp; P Maestrelli; A Ciaccia; L M Fabbri Journal: Am J Respir Crit Care Med Date: 1999-08 Impact factor: 21.405
Authors: P M van Grunsven; C P van Schayck; J P Derenne; H A Kerstjens; T E Renkema; D S Postma; T Similowski; R P Akkermans; P C Pasker-de Jong; P N Dekhuijzen; C L van Herwaarden; C van Weel Journal: Thorax Date: 1999-01 Impact factor: 9.139
Authors: R A Pauwels; C G Löfdahl; L A Laitinen; J P Schouten; D S Postma; N B Pride; S V Ohlsson Journal: N Engl J Med Date: 1999-06-24 Impact factor: 91.245
Authors: Keith L Hattotuwa; Mariusz J Gizycki; Tareq W Ansari; Peter K Jeffery; Neil C Barnes Journal: Am J Respir Crit Care Med Date: 2002-06-15 Impact factor: 21.405
Authors: Timothy W Shipley; Heather M Kling; Alison Morris; Sangita Patil; Jan Kristoff; Siobhan E Guyach; Jessica E Murphy; Xiuping Shao; Frank C Sciurba; Robert M Rogers; Thomas Richards; Paul Thompson; Ronald C Montelaro; Harvey O Coxson; James C Hogg; Karen A Norris Journal: J Infect Dis Date: 2010-07-15 Impact factor: 5.226
Authors: C E Brightling; S McKenna; B Hargadon; S Birring; R Green; R Siva; M Berry; D Parker; W Monteiro; I D Pavord; P Bradding Journal: Thorax Date: 2005-03 Impact factor: 9.139
Authors: Diana C Grootendorst; Stefanie A Gauw; Renate M Verhoosel; Peter J Sterk; Jeannette J Hospers; Dirk Bredenbröker; Thomas D Bethke; Pieter S Hiemstra; Klaus F Rabe Journal: Thorax Date: 2007-06-15 Impact factor: 9.139